Sevelamer Carbonate API is a non-absorbed, metal-free and calcium-free phosphate-binding polymer used in pharmaceutical formulations for the management of elevated serum phosphorus levels in patients with chronic kidney disease. Unlike conventional small-molecule pharmaceutical ingredients, sevelamer carbonate is a synthetic, cross-linked polymeric drug substance. FDA identifies sevelamer as a synthetic random cross-linked copolymer derived from allylamine and epichlorohydrin, while sevelamer carbonate represents the carbonate salt form of the polymer.
Sevelamer Carbonate is identified by CAS Number 845273-93-0 and FDA UNII 9YCX42I8IU. Its polymeric nature means that a conventional single molecular structure and fixed molecular weight do not adequately describe the pharmaceutical material. Database representations may provide an empirical repeating-unit formula and calculated molecular weight, but these should not be interpreted as the molecular weight of a discrete small molecule. PubChem and USP identify Sevelamer Carbonate as a polymeric substance.
The pharmaceutical activity of Sevelamer Carbonate is based on its ability to bind phosphate within the gastrointestinal tract. The polymer contains multiple amine groups that become protonated under gastrointestinal conditions. These positively charged amine sites interact with negatively charged phosphate ions through ionic interactions and hydrogen bonding.
Because sevelamer is not absorbed systemically to a significant extent, the polymer acts locally in the gastrointestinal tract. By binding dietary phosphate and reducing its absorption, Sevelamer Carbonate helps reduce serum phosphorus concentrations.
Current prescribing information identifies Sevelamer Carbonate as a phosphate binder indicated for the control of serum phosphorus in adults and pediatric patients with chronic kidney disease on dialysis.
Sevelamer Carbonate is a white to off-white, non-crystalline powder. The European Medicines Agency describes the drug substance as free-flowing and insoluble in tested solvents. USP likewise describes Sevelamer Carbonate as a white to off-white powder that is insoluble in water and organic solvents.
The substance is also hygroscopic, making moisture control an important consideration during manufacturing, packaging and storage. Regulatory information describes sevelamer carbonate as amorphous, hygroscopic and hydrophilic while remaining insoluble in water. A 1% aqueous slurry has been reported to have a pH range of approximately 8.0–10.5.
A database representation gives the empirical formula C₇H₁₄ClNO₄ and a calculated molecular weight of 211.64 g/mol, but these values represent a simplified repeating/component representation rather than the molecular weight of the actual cross-linked polymer.
Sevelamer Carbonate is manufactured through controlled polymer chemistry rather than conventional small-molecule synthesis. Regulatory documentation describes production involving cross-linking of poly(allylamine hydrochloride) using epichlorohydrin, followed by conversion toward the carbonate form.
The EMA describes a manufacturing process in which the polymer is cross-linked to produce the insoluble polymer network, treated to generate the free-base form, washed to remove water-soluble impurities, reacted with carbon dioxide to form Sevelamer Carbonate and subsequently dried, screened and packaged.
Because the material is a polymer, control of the manufacturing process is essential for maintaining consistent functional characteristics. Parameters such as polymer composition, degree of cross-linking, amine content, carbonate content, particle characteristics, swelling behavior and phosphate-binding performance can influence the quality of the final API.
Quality control for Sevelamer Carbonate API differs substantially from conventional APIs. FDA recommends comparative physicochemical characterization to establish API sameness because the material is polymeric. FDA guidance discusses characterization of the polymer structure, manufacturing process and relevant physicochemical properties rather than relying solely on a conventional molecular assay.
The USP proposal for the drug substance includes analytical controls such as identification, limits for epichlorohydrin and allylamine, phosphate-binding capacity, and physicochemical characterization. USP also identifies Sevelamer Carbonate and polyallylamine hydrochloride reference standards for analytical testing.
The EMA active-substance control strategy includes appearance, ATR-FTIR identification, loss on drying, titratable amines, carbonate content, swell index, soluble oligomers, residual substances, allylamine, heavy metals, residue on ignition, total halides as chloride and microbial limits.
Phosphate-binding capacity is one of the most important functional characteristics of Sevelamer Carbonate. Since the therapeutic activity depends on the polymer's ability to bind phosphate, pharmaceutical quality control cannot rely exclusively on conventional HPLC assay.
USP's proposed drug-substance monograph specifically includes a phosphate-binding-capacity test, while research-grade reference material may report phosphate-binding values such as approximately 4.89 mmol/g. However, research-product values should not automatically be adopted as a pharmaceutical API release specification.
For commercial pharmaceutical production, the acceptance range should therefore be taken from the applicable validated product/API specification rather than an unrelated research-grade certificate.
Because the manufacturing process uses polymerization and cross-linking chemistry, control of process-related substances is particularly important. Allylamine and epichlorohydrin are specifically addressed in the USP analytical framework for Sevelamer Carbonate.
The EMA also identifies residual substances, allylamine, soluble oligomers, total halides and elemental impurities as relevant quality attributes. Appropriate validated chromatographic, spectroscopic and physicochemical procedures should therefore be used to demonstrate batch consistency.
A pharmaceutical-grade Sevelamer Carbonate API Manufacturer in India should maintain specialized controls appropriate for polymeric drug substances. Conventional small-molecule specifications alone are insufficient for demonstrating the quality and functional performance of sevelamer carbonate.
Important manufacturing controls include polymer composition, cross-linking conditions, washing efficiency, carbonate conversion, moisture control, particle characteristics, swelling behavior, phosphate-binding capacity and control of residual process substances.
Manufacturing documentation should provide adequate batch traceability and analytical evidence. Depending on customer and regulatory requirements, documentation may include a Certificate of Analysis, specification sheet, analytical procedures, impurity profile, residual-substance data, functional testing and stability information.
Sevelamer Carbonate is hygroscopic, so moisture protection is particularly important. The API should be packaged in a suitable moisture-barrier container and handled under controlled environmental conditions.
The packaging system should maintain the physical and functional characteristics of the polymer throughout storage and transportation. Appropriate packaging should protect against excessive moisture and contamination while maintaining batch integrity.
The principal pharmaceutical application of Sevelamer Carbonate is as a phosphate binder for the control of serum phosphorus in chronic kidney disease.
The API is used in pharmaceutical dosage forms including tablets and powder formulations for oral suspension. Current U.S. labeling includes sevelamer carbonate tablets for adults and pediatric patients aged six years and older with chronic kidney disease on dialysis.
Sevelamer Carbonate provides a non-calcium, non-aluminum approach to phosphate binding and is therefore an important pharmaceutical ingredient in the management of hyperphosphatemia associated with chronic kidney disease.
Sevelamer Carbonate is a specialized polymeric pharmaceutical ingredient requiring a quality-control strategy tailored to its unique physicochemical and functional properties.
A reliable Sevelamer Carbonate API Manufacturer in India should focus on:
With appropriate polymer-specific manufacturing controls and validated analytical procedures, Sevelamer Carbonate API can provide a consistent pharmaceutical raw material for the development and manufacture of phosphate-binding medicines.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| pH (1% Solution) | 8.0–10.5 |